Merck has announced a partnership with Palantir Technologies, that is expected to leverage Palantir’s advanced data analytics capabilities. Financial details of the agreement were not disclosed.

Initially, Merck will apply Palantir’s technology to cancer treatment and patient services. Ultimately the company says it plans to deploy Palantir’s technology across all three of the its business sectors – Healthcare, Life Science and Performance Materials.

According to a statement released by Merck, the partnership is expected to launch with three initiatives:

  • Medical Research & Drug Development: The partnership is expected to increase precision of the drug development process by developing a collaborative data and analytics platform, so that Merck researchers can analyze real-world and bioinformatics data to understand the patients who may benefit most.
  • Global Patient Intimacy: The partnership is expected to improve the experience of patients using Merck products, by utilizing large-scale data sources.
  • Global Supply Chain: The data and analytics platform is expected to improve supply chain forecasting and agility.

“As a science and technology company, we are tackling the greatest challenges in healthcare, life science and performance materials. Now we are teaming up with Palantir since developing breakthrough technologies requires superior data analytics capabilities, and Palantir optimally complements our skills in that respect,” said Stefan Oschmann, chairman of the executive board and CEO of Merck, during the announcement of this partnership on Thursday.

[Image courtesy: Merck]